LAWRENCEVILLE - IMUNON, Inc. (NASDAQ: IMNN), a biotechnology firm engaged in immunotherapy and vaccine development, has announced the publication of a study showcasing the efficacy of its DNA-based vaccine modality, PlaCCine, in the peer-reviewed journal Vaccine. The study indicates that PlaCCine's formulation, which targets SARS-CoV-2 spike proteins, has demonstrated strong immunogenicity and protection in mice.
The research detailed how IMUNON's proprietary functionalized polymer shields DNA from degradation and, when combined with an adjuvant, increases protein expression. The resulting DNA vaccine, stable for up to a year at 4°C, induced spike-specific neutralizing antibodies and cytotoxic T cells in mice. Furthermore, the vaccine's immune response was found to suppress viral replication effectively in vivo.
PlaCCine's design allows for the insertion of multiple genetic sequences, suggesting the possibility of broader protection against various pathogens. IMUNON is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and anticipates initiating a Phase 1/2 study in the spring.
Dr. Corinne Le Goff, president and CEO of IMUNON, expressed optimism about the vaccine modality's potential to provide potent and durable immunity against COVID-19, emphasizing the ease of handling and the ability to incorporate multiple antigens into a single plasmid.
IMUNON's technology is being developed across four modalities, with applications ranging from solid tumor treatments to infectious disease vaccines. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 2 development.
This news is based on a press release statement.
InvestingPro Insights
As IMUNON, Inc. (NASDAQ: IMNN) continues to make strides in the biotechnology landscape with its innovative vaccine modality, PlaCCine, it's important for investors to consider the financial health and market performance of the company. Based on data from InvestingPro, IMUNON's market capitalization stands at a modest 5.05 million USD, reflecting its status as a smaller player in the biotech sector. The company's revenue for the last twelve months as of Q3 2023 was reported at 0.12 million USD, with a significant revenue growth decline of -75%. This decline may raise concerns about the company's sales trajectory.
InvestingPro Tips suggest that while IMUNON holds more cash than debt on its balance sheet, it is quickly burning through cash and suffers from weak gross profit margins. These financial challenges are compounded by the fact that analysts do not anticipate the company will be profitable this year. In the context of the company's recent scientific publication and ongoing research efforts, these financial metrics highlight the inherent risks and volatility often associated with investing in biotech startups.
Investors should also note the stock's recent performance, with a significant price decline over the last three months of -39.61%, and a six-month total return of -52.01%. Despite these challenges, the company's liquid assets do exceed its short-term obligations, which may provide some financial flexibility as it advances its clinical programs.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available that delve deeper into IMUNON's financials and market performance. To learn more and to take advantage of these insights, visit https://www.investing.com/pro/IMNN and use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 11 more tips listed in InvestingPro, investors can gain a fuller understanding of IMUNON's investment profile.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.